Pre-Conference Seminar Day

**This ran Tuesday 26 April, 2022** 

This pre-conference seminar day is an excellent opportunity to gain an overview of the neoantigen space. Join us as we address how we have got to where we are with neoantigen-based immunotherapies and personalised cancer vaccines and explore how far we will go with their development.

9:50 am Chair’s Opening Remarks

Achieving Clinical Benefits from Cancer Vaccines – A Road to Success

10:00 am Discussion – Why Has No Vaccine Made it to Market Yet?


  • Understanding why recombinant cancer vaccines are expected to hold significant market share in the cancer vaccines market
  • Realising the importance of DNA encoding, an antigen which stimulates an immune response into mammalian cells
  • Uncovering numerous studies being conducted in the field of viral recombinant cancer vaccines which may reap positive results in future

10:30 am Bringing Personalised Cancer Vaccines into the Clinic for Commercial Success


  • Identifying the best neoantigens to use in the clinic
  • Understanding who the best patients are that would have the strongest benefit
    from neoantigen based vaccines
  • Utilising our current knowledge to bring this therapy into market and paving the
    way for a clear path to commercialisation

11:00 am Morning Refreshments & Structured Networking


Have in-person 1-to-1 business introductions with other leaders and decision-makers prioritising neoantigen identification and cancer vaccine development

11:30 am Translating T Cell Responses Generated by Vaccines into Lasting Benefits for Patients


  • Discussing the powerful combination immunotherapies that are needed for the
    treatment of metastatic patents
  • Determining the vaccination platform, the magnitude and quality of neoantigen
    induced T cells
  • Interrogating T cells infiltrating the tumour to dissect the relative contribution of
    vaccine induced T cells

12:00 pm Avenues to Non-Canonical T Cell Antigen Discovery in Cancer

  • Nicola Ternette Principle Investigator, Antigen Discovery, University of Oxford


• Developing and validating new methods to simultaneously assay multiple
microbial antibodies in plasma
trials of real subjects
• Discussing the importance of plasma monitoring and how this proves to be a
useful tool for clinical decision making
• Evaluating the time and cost benefits of using new techniques compared to
ELISA methods
• Offering simultaneous quantification of several immune checkpoint inhibitors
likely to be associated in patients

12:30 pm Lunch Break & Networking

1:30 pm Tumour Neoantigens and the Host Microbiome: Implications for Tumour Immune Surveillance and Cancer Immunotherapy

  • Maximilian Bosch Project Manager, Lung Center, Cantonal Hospital St.Gallen, Switzerland


• Discussing immunological visibility and immune evasion
• Highlighting the relevance of tumour neoantigens in medical oncology
• Examining current markers for predicting responsiveness

2:00 pm Recent Progress Within Immunopeptidome Prediction

  • Morten Nielsen Professor Department of Health Technology, The Technical University of Denmark


• Predicting the dark-immunopeptidome
• Predicting T cell targets
• Understanding the CEDAR initiative

14:30 pm Afternoon Refreshments & Structured Networking


Have in-person 1-to-1 business introductions with other leaders and decisionmakers
prioritising neoantigen identification and cancer vaccine development

Retroviral Antigens – Uncovering a New Avenue


Attending this afternoon seminar session is the perfect chance to uncover an emerging and robust opportunity within the Neoantigen field. Learn about retroviral antigens and partake in discussions and Q&As to utilise this unparalleled topic in expanding your pipelines.

3:00 pm Human Endogenous Retroviruses (HERVs) Represent a Source of Shared Tumour Epitopes Inducing High Avidity Cytotoxic T Cells for Cancer Immunotherapy

  • Stephane Depil Onco-Hematology Specialist Immuno-Oncology & Cancer Immunotherapy, Centre Leon Berard


• Exploring sequencing and data analysis issues being used to identify retrovirus antigens
• Learning how shared they really are and if they are shared based on disease
state or on populations
• Uncovering if all retroviruses are disease-based


4:00 pm Chair’s Closing Remarks